Eupraxia Pharmaceuticals (EPRX)
NASDAQ:EPRX
Want to see EPRX full AI Analyst Report?
EPRX Stock Chart & Stats
$7.10
-$0.02(-0.66%)
At close: 4:00 PM EST
$7.10
-$0.02(-0.66%)
Day’s Range― - ―
52-Week Range$3.67 - $9.32
Previous CloseN/A
Volume2.60K
Average Volume (3M)148.90K
Market Cap
$473.95M
Enterprise Value$189.42M
Total Cash (Recent Filing)$80.42M
Total Debt (Recent Filing)$154.08K
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding61,503,180
10 Day Avg. Volume43,828
30 Day Avg. Volume148,898
Financial Highlights & Ratios
PEG Ratio-5.41
Price to Book (P/B)5.04
Price to Sales (P/S)0.00
P/FCF Ratio-13.91
Enterprise Value/Market Cap0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-622.90
Enterprise Value/Ebitda-4.68
Forecast
1Y Price Target
$14.80Price Target Upside108.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.72
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityEarly clinical data show durable symptom and tissue improvements after a single administration in higher dose patients, suggesting the therapy could enable infrequent dosing and improved patient adherence compared with frequent biologic or steroid regimens.
Differentiated Delivery TechnologyDiffuSphere extended‑release, site‑specific delivery may maintain therapeutic drug levels in the esophagus while limiting systemic exposure, supporting potential for infrequent dosing and a competitive advantage versus current steroid options.
Market OpportunityAnalyst highlights that the addressable market for eosinophilic esophagitis may be materially larger than commonly cited estimates, supporting significant commercial upside for EP-104GI if adoption expands beyond diagnosed patients.
Bears Say
Device And Dosing ReliabilityInitial catheter clogging that reduced delivered drug in earlier cohorts raises concerns about consistent dose delivery and may require device or administration changes before broader use.
Financing And Milestone UncertaintyEquity financing raised dilution and higher projected operating expenses, while limited detail on clinical results and regulatory timelines increases near‑term milestone and valuation uncertainty.
Trial Size And Statistical UncertaintySmall patient numbers in early cohorts limit the strength of conclusions and necessitate larger randomized trials to confirm observed efficacy and durability signals.
Eupraxia Pharmaceuticals News
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was $3.67 and its highest was $9.32 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is $473.95M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Aug 07, 2026 which is in 91 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 61,503,180 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in EPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eupraxia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.80 (108.45% Upside)
$14.80 (108.45% Upside)
Insider Transactions
Bought Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 30.4%
Last 30 Days ▲ 30.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.00%
12-Months-Change
Fundamentals
Return on Equity
-63.85%
Trailing 12-Months
Asset Growth
134.99%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
EPRX Stock 12 Month Forecast
Average Price Target
$14.80
▲(108.45% Upside)
Technical Analysis
―
Entheon Biomedical
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Mindbio Therapeutics Corp.
―
Ownership Overview
11.07% Insiders
0.03% Mutual Funds
0.56% Other Institutional Investors
88.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---